An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors

被引：8
|
作者：
Rodon, J. [1 ]
Li, J. [2 ]
Xue, J. [2 ]
Diao, Y. [3 ]
Xu, Y. [3 ]
Liu, G. [3 ]
Rao, C. [3 ]
Fan, B. [3 ]
Cheng, Y. [3 ]
Wang, J. [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Early Drug Dev, Houston, TX 77030 USA
[2] Shanghai East Hosp, Oncol Dept, Shanghai, Peoples R China
[3] Sichuan Kelun Biotech Biopharmaceut Co Ltd, Clin Res Ctr, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
514O
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [1] SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.
    Liu, Yongheng
    Lian, Wei
    Zhao, Xi
    Diao, Yina
    Xu, Jian
    Xiao, Liang
    Qing, Yan
    Xue, Tongtong
    Wang, Jingyi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors
    Tolcher, Anthony W.
    Wu, Xiaohua
    Zhang, Jian
    Barve, Minal A.
    Gabrail, Nashat Y.
    Sommerhalder, David
    Rivera, Ildefonso I. Rodriguez
    Wilks, Sharon
    Wu, Yong
    Liu, Rujiao
    Gao, Shuiping
    Valiyil, Akhilkrishna
    Sayi, Ntombizodwa
    Germa, Caroline
    Qi, Charlie
    Chen, Lei
    Yu, Steven
    Yao, Jenny
    Zhu, Xuelian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors
    Ahnert, Jordi Rodon
    Spigel, David R.
    Kremer, Jill
    Jin, Leah
    Benhadji, Karim Adnane
    Gil, Maciej
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
  • [5] Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study
    Moore, Kathleen N.
    Sabanathan, Dhanusha
    Du, Yiqun
    Duan, Huaxin
    Li, Xiumin
    Wang, Feng
    Marathe, Omkar
    Yang, Hua
    Makker, Vicky
    Growdon, Whitfield
    Coward, Jim
    Zhao, Peng
    Liu, Liming
    Shi, Rong
    Liu, Shengxue
    Gu, Wei
    Qiu, Yang
    Zhu, Zhongyuan
    Zhang, Jian
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors
    Rivera, Ismael Rodriguez
    Shen, Lin
    Kummar, Shivaani
    Barve, Minal
    Germa, Caroline
    Qi, Chuan
    Chen, Lei
    Milata, Jenny
    Yao, Jenny
    Shen, Li
    Zhu, Xuelian
    CANCER RESEARCH, 2024, 84 (06)
  • [7] A PHASE 1, FIRST IN HUMAN, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF TST005 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Chen, Lei
    Tolcher, Anthony
    Gabrail, Nashat
    Barve, Minal
    Wu, Xiaohua
    Zhang, Jian
    Shi, Michael
    Qi, Chuan
    Yu, Steven
    Yao, Jenny
    Wang, Jianming
    Cavanaugh, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A802 - A802
  • [8] Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors
    Arkenau, H-T.
    Guthrie, T.
    Mekhail, T.
    Cortinovis, D.
    Antonuzzo, L.
    Bruce, J. Y.
    Gabrail, N.
    Anderson, I.
    Oh, S. C.
    Oh, S. Y.
    Nott, L.
    Shah, M. A.
    Sanborn, R. E.
    Oh, D-Y.
    Cho, J. Y.
    Lin, C-C.
    Lee, A.
    Wang, Y.
    Wang, Z.
    Sher, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S671 - S672
  • [9] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Beecroft, Claire
    Gao, Bo
    Park, John
    Wilkinson, Kate
    Zhang, Karl
    Yan, Xiangyun
    Lv, Yuan
    CANCER RESEARCH, 2024, 84 (07)
  • [10] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Park, John J.
    Gao, Bo
    Beecroft, Claire
    Wilkinson, Kate Jessica
    Parsonson, Andrew
    Zhang, Karl
    Yan, Xiangyun
    Wang, Ni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345